6 completed, 2 active not recruiting, 1 enrolling by invitation, 1 withdrawn. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Active not recruiting 2, Enrolling by invitation 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Sexual Infantilism: new trials by email Literature Review of Sexual Infantilism trials Research Report on Sexual Infantilism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) Bivamelagon - Hypothalamic Obesity | Phase 2 | Enrolling by invitation | Rhythm Pharmaceuticals, Inc. | 25 | 2025-11-10 | 2026-02-10 |
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo - Hypothalamic Obesity, Hypothalamic Tumor | Phase 2 | Active not recruiting | Seattle Children's Hospital | 24 | 2025-03-01 | 2026-10-16 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Bivamelagon, Placebo - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-07-11 | 2026-10-30 |
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718 - Hypothalamic Obesity, Prader-Willi Syndrome | Phase 1 / Phase 2 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 111 | 2024-03-05 | 2026-10-09 |
| Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Placebo, Tesomet - Hypothalamic Obesity | Phase 2 | Withdrawn | Saniona | 2021-11-11 | 2022-12-13 | |
| Open-Label Study of Setmelanotide in Hypothalamic Obesity Setmelanotide - Hypothalamic Obesity | Phase 2 | Completed | Rhythm Pharmaceuticals, Inc. | 18 | 2021-06-07 | 2025-02-07 |
| Intranasal Oxytocin in Hypothalamic Obesity Syntocinon, Placebo (for Syntocinon) - Craniopharyngioma, Hypothalamic Obesity | Phase 2 | Completed | Shana McCormack, MD | 18 | 2016-10-01 | 2022-10-05 |
| Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Exenatide - Obesity, Overweight | Phase 2 | Completed | Vanderbilt University Medical Center | 10 | 2012-06-01 | 2017-03-03 |
| Effects of Exenatide on Hypothalamic Obesity Exenatide - Hypothalamic Obesity | Phase 1 / Phase 2 | Completed | Children's Hospitals and Clinics of Minnesota | 19 | 2010-01-01 | 2019-10-08 |
| Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Diazoxide, Metformin - Hypothalamic Obesity | Phase 2 | Completed | The Hospital for Sick Children | 9 | 2006-05-01 | 2017-11-17 |
Craniopharyngioma (4) · Obesity (2) · Hypothalamic Neoplasms (1) · Overweight (1) · Prader-Willi Syndrome (1)
Congenital Abnormalities (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Disorders of Sex Development (10) · Endocrine System Diseases (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Gonadal Disorders (10) · Gonadal Dysgenesis (10) · Hypogonadism (10) · Male Urogenital Diseases (10) · Urogenital Abnormalities (10) · Urogenital Diseases (10) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4)
Exenatide (2) · Diazoxide (1) · Metformin (1) · Metoprolol (1) · Oxytocin (1) · Phentermine (1) · Qsymia (1) · Tesofensine (1) · setmelanotide (1)
Rhythm Pharmaceuticals, Inc. (4) · Children's Hospitals and Clinics of Minnesota (1) · Saniona (1) · Seattle Children's Hospital (1) · Shana McCormack, MD (1) · The Hospital for Sick Children (1) · Vanderbilt University Medical Center (1)
United States (9) · United Kingdom (2) · Canada (1)
David Meeker, MD (3) · Shana E McCormack, MD (2) · Ashley Shoemaker, M.D. (1) · Christian L Roth, MD (1) · David Meeker (1) · Jill Hamilton, MD (1) · M. Jennifer Abuzzahab, MD (1) · Sophie Guillaume, MS (1)